Noventra Pharma | Retatrutide 32mg | Compound Peptide Vial
High-Strength Triple Receptor Metabolic Research Compound
Retatrutide is an investigational peptide studied for its multi-receptor activity across GLP-1, GIP, and glucagon pathways.
It is widely referenced in scientific research exploring complex metabolic signalling, energy regulation mechanisms, and multi-pathway peptide interactions within controlled laboratory environments.
Developed as a 32mg research compound in vial format, this formulation is designed for laboratory preparation and advanced investigation where receptor activity profiling and metabolic peptide research are of interest.
Key Benefits – Noventra Retatrutide 32mg Compound Peptide Vial (“Triple G” Agonist)
• Triple receptor research compound targeting GLP-1, GIP, and glucagon pathways
• Investigated in metabolic signalling and endocrine research models
• Of interest in multi-pathway peptide interaction studies
• 32mg vial format designed for laboratory preparation use
• Studied in advanced metabolic peptide research contexts
• High-purity investigational formulation from Noventra
• Manufactured for stability, consistency, and research reliability
• Strictly intended for laboratory research use only
⚖️ DISCLAIMER
This product is intended strictly for laboratory research purposes only. It is not a medicine and has not been evaluated or approved by the South African Health Products Regulatory Authority (SAHPHRA) for human or animal use.
This product is supplied strictly for laboratory research purposes only and is not intended for human consumption.
Products sold on this website are not intended to diagnose, treat, cure, or prevent any disease.
By purchasing, the customer confirms they are qualified to handle and use this product in accordance with applicable laws and regulations.
